

**Olaparib**

**PROpel**

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS


### Quality of life



### Serious and disabling adverse effects



### Other adjustments



## SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: EMA: Olaparib is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. FDA: olaparib with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

Experimental Arm: Olaparib + Abiraterone + prednisone or prednisolone

Control Arm: Placebo + abiraterone + prednisone or prednisolone

